GlassScriptPhysician profile
Anil M Chawla
NPI 1922066760
$1,474.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $110 · 2021: $106 · 2022: $290 · 2023: $163 · 2024: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $287.93 | 2022-2024 | Watchman Flx |
| Abbvie INC. | $144.45 | 2021-2024 | Teflaro |
| Astrazeneca Pharmaceuticals LP | $135.16 | 2019-2024 | Farxiga |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
| Novo Nordisk INC | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Lexicon Pharmaceuticals, INC. | $122.80 | 2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $121.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $106.62 | 2019-2023 | Shingrix, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2019 | |
| Mylan Specialty L.P. | $13.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.